Motor properties of Myosin 5c are modulated by tropomyosin isoforms and inhibited by pentabromopseudilin.

Myosin 5c immunohistochemistry molecular docking pentabromopseudilin tropomyosin

Journal

Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006

Informations de publication

Date de publication:
2024
Historique:
received: 29 02 2024
accepted: 20 03 2024
medline: 12 4 2024
pubmed: 12 4 2024
entrez: 12 4 2024
Statut: epublish

Résumé

Myosin 5c (Myo5c) is a motor protein that is produced in epithelial and glandular tissues, where it plays an important role in secretory processes. Myo5c is composed of two heavy chains, each containing a generic motor domain, an elongated neck domain consisting of a single α-helix with six IQ motifs, each of which binds to a calmodulin (CaM) or a myosin light chain from the EF-hand protein family, a coiled-coil dimer-forming region and a carboxyl-terminal globular tail domain. Although Myo5c is a low duty cycle motor, when two or more Myo5c-heavy meromyosin (HMM) molecules are linked together, they move processively along actin filaments. We describe the purification and functional characterization of human Myo5c-HMM co-produced either with CaM alone or with CaM and the essential and regulatory light chains Myl6 and Myl12b. We describe the extent to which cofilaments of actin and Tpm1.6, Tpm1.8 or Tpm3.1 alter the maximum actin-activated ATPase and motile activity of the recombinant Myo5c constructs. The small allosteric effector pentabromopseudilin (PBP), which is predicted to bind in a groove close to the actin and nucleotide binding site with a calculated ΔG of -18.44 kcal/mol, inhibits the motor function of Myo5c with a half-maximal concentration of 280 nM. Using immunohistochemical staining, we determined the distribution and exact localization of Myo5c in endothelial and endocrine cells from rat and human tissue. Particular high levels of Myo5c were observed in insulin-producing β-cells located within the pancreatic islets of Langerhans.

Identifiants

pubmed: 38606007
doi: 10.3389/fphys.2024.1394040
pii: 1394040
pmc: PMC11008601
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1394040

Informations de copyright

Copyright © 2024 Kengyel, Palarz, Krohn, Marquardt, Greve, Heiringhoff, Jörns and Manstein.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

András Kengyel (A)

Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany.
Department of Biophysics, University of Pécs Medical School, Pécs, Hungary.

Philip M Palarz (PM)

Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany.

Jacqueline Krohn (J)

Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany.

Anja Marquardt (A)

Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany.

Johannes N Greve (JN)

Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany.

Robin Heiringhoff (R)

Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany.

Anne Jörns (A)

Institute of Clinical Biochemistry, Hannover Medical School, Hannover, Germany.

Dietmar J Manstein (DJ)

Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany.

Classifications MeSH